638 related articles for article (PubMed ID: 16288294)
1. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease.
Astrinidis A; Henske EP
Oncogene; 2005 Nov; 24(50):7475-81. PubMed ID: 16288294
[TBL] [Abstract][Full Text] [Related]
2. Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways.
Kwiatkowski DJ; Manning BD
Hum Mol Genet; 2005 Oct; 14 Spec No. 2():R251-8. PubMed ID: 16244323
[TBL] [Abstract][Full Text] [Related]
3. The mTOR/S6K signalling pathway: the role of the TSC1/2 tumour suppressor complex and the proto-oncogene Rheb.
Nobukini T; Thomas G
Novartis Found Symp; 2004; 262():148-54; discussion 154-9, 265-8. PubMed ID: 15562827
[TBL] [Abstract][Full Text] [Related]
4. The expression of hamartin, the product of the TSC1 gene, in normal human tissues and in TSC1- and TSC2-linked angiomyolipomas.
Plank TL; Logginidou H; Klein-Szanto A; Henske EP
Mod Pathol; 1999 May; 12(5):539-45. PubMed ID: 10349994
[TBL] [Abstract][Full Text] [Related]
5. Tuberin activates the proapoptotic molecule BAD.
Freilinger A; Rosner M; Krupitza G; Nishino M; Lubec G; Korsmeyer SJ; Hengstschläger M
Oncogene; 2006 Oct; 25(49):6467-79. PubMed ID: 16702951
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of the TSC1 and TSC2 genes in Japanese patients with pulmonary lymphangioleiomyomatosis.
Sato T; Seyama K; Fujii H; Maruyama H; Setoguchi Y; Iwakami S; Fukuchi Y; Hino O
J Hum Genet; 2002; 47(1):20-8. PubMed ID: 11829138
[TBL] [Abstract][Full Text] [Related]
7. Metastasis of benign tumor cells in tuberous sclerosis complex.
Henske EP
Genes Chromosomes Cancer; 2003 Dec; 38(4):376-81. PubMed ID: 14566858
[TBL] [Abstract][Full Text] [Related]
8. Analysis of 65 tuberous sclerosis complex (TSC) patients by TSC2 DGGE, TSC1/TSC2 MLPA, and TSC1 long-range PCR sequencing, and report of 28 novel mutations.
Rendtorff ND; Bjerregaard B; Frödin M; Kjaergaard S; Hove H; Skovby F; Brøndum-Nielsen K; Schwartz M;
Hum Mutat; 2005 Oct; 26(4):374-83. PubMed ID: 16114042
[TBL] [Abstract][Full Text] [Related]
9. Platelet-derived growth factor-induced p42/44 mitogen-activated protein kinase activation and cellular growth is mediated by reactive oxygen species in the absence of TSC2/tuberin.
Finlay GA; Thannickal VJ; Fanburg BL; Kwiatkowski DJ
Cancer Res; 2005 Dec; 65(23):10881-90. PubMed ID: 16322235
[TBL] [Abstract][Full Text] [Related]
10. Overlapping neurologic and cognitive phenotypes in patients with TSC1 or TSC2 mutations.
Jansen FE; Braams O; Vincken KL; Algra A; Anbeek P; Jennekens-Schinkel A; Halley D; Zonnenberg BA; van den Ouweland A; van Huffelen AC; van Nieuwenhuizen O; Nellist M
Neurology; 2008 Mar; 70(12):908-15. PubMed ID: 18032745
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of mTOR in tuberous sclerosis.
Sampson JR
Biochem Soc Trans; 2009 Feb; 37(Pt 1):259-64. PubMed ID: 19143643
[TBL] [Abstract][Full Text] [Related]
12. Antisense suppression of TSC1 gene product, hamartin, enhances neurite outgrowth in NGF-treated PC12h cells.
Floricel F; Higaki K; Maki H; Nanba E; Ninomiya H; Ohno K
Brain Dev; 2007 Sep; 29(8):502-9. PubMed ID: 17376623
[TBL] [Abstract][Full Text] [Related]
13. Distinct effects of single amino-acid changes to tuberin on the function of the tuberin-hamartin complex.
Nellist M; Sancak O; Goedbloed MA; Rohe C; van Netten D; Mayer K; Tucker-Williams A; van den Ouweland AM; Halley DJ
Eur J Hum Genet; 2005 Jan; 13(1):59-68. PubMed ID: 15483652
[TBL] [Abstract][Full Text] [Related]
14. Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb.
Tee AR; Manning BD; Roux PP; Cantley LC; Blenis J
Curr Biol; 2003 Aug; 13(15):1259-68. PubMed ID: 12906785
[TBL] [Abstract][Full Text] [Related]
15. Tuberin, the tuberous sclerosis complex 2 tumor suppressor gene product, regulates Rho activation, cell adhesion and migration.
Astrinidis A; Cash TP; Hunter DS; Walker CL; Chernoff J; Henske EP
Oncogene; 2002 Dec; 21(55):8470-6. PubMed ID: 12466966
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary lymphangioleiomyomatosis (LAM): progress and current challenges.
Goncharova EA; Krymskaya VP
J Cell Biochem; 2008 Feb; 103(2):369-82. PubMed ID: 17541983
[TBL] [Abstract][Full Text] [Related]
17. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins.
Zhang Y; Gao X; Saucedo LJ; Ru B; Edgar BA; Pan D
Nat Cell Biol; 2003 Jun; 5(6):578-81. PubMed ID: 12771962
[TBL] [Abstract][Full Text] [Related]
18. Analysis of both TSC1 and TSC2 for germline mutations in 126 unrelated patients with tuberous sclerosis.
Niida Y; Lawrence-Smith N; Banwell A; Hammer E; Lewis J; Beauchamp RL; Sims K; Ramesh V; Ozelius L
Hum Mutat; 1999; 14(5):412-22. PubMed ID: 10533067
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of growth of tuberous sclerosis complex 2 null cells by atorvastatin is associated with impaired Rheb and Rho GTPase function and reduced mTOR/S6 kinase activity.
Finlay GA; Malhowski AJ; Liu Y; Fanburg BL; Kwiatkowski DJ; Toksoz D
Cancer Res; 2007 Oct; 67(20):9878-86. PubMed ID: 17942919
[TBL] [Abstract][Full Text] [Related]
20. Mutational analysis of TSC1 and TSC2 in Korean patients with tuberous sclerosis complex.
Choi JE; Chae JH; Hwang YS; Kim KJ
Brain Dev; 2006 Aug; 28(7):440-6. PubMed ID: 16554133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]